247 related articles for article (PubMed ID: 29869106)
1. Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer.
Dalal AA; Gagnon-Sanschagrin P; Burne R; Guérin A; Gauthier G; Small T; Niravath P
Adv Ther; 2018 Jun; 35(6):768-778. PubMed ID: 29869106
[TBL] [Abstract][Full Text] [Related]
2. Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.
Biskupiak J; Oderda G; Brixner D; Tang D; Zacker C; Dalal AA
J Manag Care Spec Pharm; 2019 Aug; 25(8):859-866. PubMed ID: 31347980
[TBL] [Abstract][Full Text] [Related]
3. Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer.
Li N; Du EX; Chu L; Peeples M; Xie J; Barghout V; Tang DH
Expert Opin Pharmacother; 2017 Aug; 18(12):1167-1178. PubMed ID: 28699804
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
[TBL] [Abstract][Full Text] [Related]
6. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
Brufsky A; Liu X; Li B; McRoy L; Layman RM
Target Oncol; 2021 Sep; 16(5):601-611. PubMed ID: 34338965
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2- patients with metastatic breast cancer.
Li J; Zhang X; Yang C; Lv Y; Yang H; Kong X; Han M; Wang Z; Ma J; Han J; Liu Y
Medicine (Baltimore); 2021 Nov; 100(44):e27710. PubMed ID: 34871262
[TBL] [Abstract][Full Text] [Related]
8. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
9. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Walker AJ; Wedam S; Amiri-Kordestani L; Bloomquist E; Tang S; Sridhara R; Chen W; Palmby TR; Fourie Zirkelbach J; Fu W; Liu Q; Tilley A; Kim G; Kluetz PG; McKee AE; Pazdur R
Clin Cancer Res; 2016 Oct; 22(20):4968-4972. PubMed ID: 27407089
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
Raphael J; Helou J; Pritchard KI; Naimark DM
Eur J Cancer; 2017 Nov; 85():146-154. PubMed ID: 28930692
[TBL] [Abstract][Full Text] [Related]
13. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
14. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.
Gauthier G; Gagnon-Sanschagrin P; Guérin A; Burne R; Small T; Niravath P; Dalal AA
Adv Ther; 2018 Apr; 35(4):503-514. PubMed ID: 29556908
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
Zhang B; Long EF
Breast Cancer Res Treat; 2019 Jun; 175(3):775-779. PubMed ID: 30847728
[TBL] [Abstract][Full Text] [Related]
16. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
Diéras V; Harbeck N; Joy AA; Gelmon K; Ettl J; Verma S; Lu DR; Gauthier E; Schnell P; Mori A; Rugo HS; Finn RS
Oncologist; 2019 Dec; 24(12):1514-1525. PubMed ID: 31217344
[TBL] [Abstract][Full Text] [Related]
18. Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.
DeMichele A; Robert N; Chen C; Kim S; Zhang Z; Lu DR; Aguilar KM; Wang Y; Li B; Schneeweiss S; Rassen JA; Gaffney M; McRoy L
Target Oncol; 2023 Jul; 18(4):543-558. PubMed ID: 37428347
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
20. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]